These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24268867)

  • 1. Cochrane Corner: evaluation of the Cochrane systematic review "antiplatelet agents for chronic kidney disease".
    Caldeira D; Vaz-Carneiro A; Costa J
    Rev Port Cardiol; 2013 Nov; 32(11):917-8. PubMed ID: 24268867
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiplatelet agents for adults with chronic kidney disease?
    BMJ; 2013 Mar; 346():f1392. PubMed ID: 23468290
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease.
    Robey RB; O'Rourke DJ
    Ann Intern Med; 2012 Aug; 157(4):302-3; author reply 303-4. PubMed ID: 22910952
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease.
    Kussmaul W
    Ann Intern Med; 2012 Aug; 157(4):302; author reply 303-4. PubMed ID: 22910951
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis.
    Palmer SC; Di Micco L; Razavian M; Craig JC; Perkovic V; Pellegrini F; Copetti M; Graziano G; Tognoni G; Jardine M; Webster A; Nicolucci A; Zoungas S; Strippoli GF
    Ann Intern Med; 2012 Mar; 156(6):445-59. PubMed ID: 22431677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiplatelet and anticoagulant therapy in chronic kidney disease].
    Cases A; Escolar G;
    Nefrologia; 2004; 24 Suppl(6):127-41, 187-235. PubMed ID: 15696903
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference.
    McCullough PA; Haapio M; Mankad S; Zamperetti N; Massie B; Bellomo R; Berl T; Anker SD; Anand I; Aspromonte N; Bagshaw SM; Bobek I; Cruz DN; Daliento L; Davenport A; Hillege H; House AA; Katz N; Maisel A; Mebazaa A; Palazzuoli A; Ponikowski P; Ronco F; Shaw A; Sheinfeld G; Soni S; Vescovo G; Zanco P; Ronco C; Berl T;
    Nephrol Dial Transplant; 2010 Jun; 25(6):1777-84. PubMed ID: 20375030
    [No Abstract]   [Full Text] [Related]  

  • 8. [Uric acid and the prevention of renal and cardiovascular disease in CKD].
    Teatini U
    G Ital Nefrol; 2012; 29 Suppl 58():S46-8. PubMed ID: 23229602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
    Gabrielli A; Bouatou Y; Saudan P
    Rev Med Suisse; 2014 Feb; 10(419):487-90, 492. PubMed ID: 24665658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?
    Jain N; Hedayati SS; Sarode R; Banerjee S; Reilly RF
    Clin J Am Soc Nephrol; 2013 Apr; 8(4):665-74. PubMed ID: 23024160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy in peripheral artery disease--antiplatelet therapy, anticoagulants, both or none.
    Tangelder MJ; van Hattum ES
    Thromb Haemost; 2010 Aug; 104(2):196-9. PubMed ID: 20508897
    [No Abstract]   [Full Text] [Related]  

  • 12. Coronary intervention in patients with diabetes, chronic renal disease, and the elderly: therapeutic implications.
    Schneider DJ
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S35-41. PubMed ID: 17917620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic kidney disease: How effective and safe are antiplatelet agents in CKD?
    Floege J; Schlieper G
    Nat Rev Nephrol; 2013 Jun; 9(6):314-6. PubMed ID: 23629644
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.
    Ibrahim H; Rao SV
    J Thromb Thrombolysis; 2017 May; 43(4):519-527. PubMed ID: 28229274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [NSAIDs and cardiovascular and renal complications].
    Valat JP
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S3-4. PubMed ID: 17080562
    [No Abstract]   [Full Text] [Related]  

  • 16. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
    Krane V; Wanner C
    Am J Kidney Dis; 2005 Mar; 45(3):607-9. PubMed ID: 15754285
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication.
    Wong PF; Chong LY; Stansby G
    JAMA; 2013 Mar; 309(9):926-7. PubMed ID: 23462789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.
    Tuttle KR; Dworkin LD; Henrich W; Greco BA; Steffes M; Tobe S; Shapiro JI; Jamerson K; Lyass A; Pencina K; Massaro JM; D'Agostino RB; Cutlip DE; Murphy TP; Cooper CJ
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1180-1188. PubMed ID: 27225988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [high on-treatment platelet reactivity in patients with chronic renal failure using acetylsalicylic acid].
    Horyniecki M; Łącka-Gaździk B; Dworaczek W; Śnit M; Łabuz-Roszak B
    Wiad Lek; 2017; 70(6 pt 1):1102-1107. PubMed ID: 29478986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
    Lepor NE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S38-48. PubMed ID: 17224890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.